The global high resolution melting analysis market size was estimated at USD 320.7 million in 2024 and is projected to reach USD 375.8 million by 2030, growing at a CAGR of 2.7% from 2025 to 2030. The market’s steady growth is being fueled by several key factors, including the increasing adoption of mutation scanning techniques, the development of novel epigenetic applications, and rising investments in research and development activities across the biotechnology and healthcare sectors.

One of the primary drivers of market expansion is the growing incidence of infectious diseases and genetic disorders worldwide, which has heightened the need for accurate and reliable genetic testing methods. Alongside this, rapid technological advancements in HRM platforms are improving their efficiency, accuracy, and throughput. The rising demand for precise genotyping and mutation detection, coupled with the growing global prevalence of genetic abnormalities, is further accelerating adoption.

Additionally, the ongoing shift toward personalized medicine is playing a pivotal role in shaping the HRM analysis market. With a greater emphasis on tailoring treatment strategies to individual genetic profiles, the need for advanced genetic testing methods has significantly increased. Rising investments in RD, coupled with regulatory support for the development and approval of molecular diagnostic tools, are also contributing to the market’s growth prospects.

High-Resolution Melting Analysis (HRM) itself is a sophisticated molecular biology technique that enables the identification of genetic variations by analyzing the melting behavior of double-stranded DNA during heating. This technique is particularly useful for detecting mutations, single nucleotide polymorphisms (SNPs), and epigenetic modifications. As healthcare systems increasingly integrate genetic testing into standard care protocols, HRM has become a vital tool in both clinical and research applications.

Furthermore, the global acceptance of genetic testing is expanding, supported by advancements in molecular biology techniques and the declining costs of genomic sequencing. These developments are making HRM analysis more accessible to healthcare providers, thereby enhancing its role in improving diagnostic accuracy, guiding therapeutic decisions, and advancing the field of precision medicine.

Key Market Trends Insights:

• In 2024, North America dominated the global high-resolution melting (HRM) analysis market, accounting for the largest revenue share of 36.0%. The region’s leadership can be attributed to advanced healthcare infrastructure, widespread adoption of molecular diagnostic technologies, and significant investments in genetic research and development. Supportive regulatory frameworks and strong funding from both government and private organizations have also reinforced North America’s market position.

• Within the region, the U.S. emerged as the leading contributor, holding the largest share of the North American HRM analysis market in 2024. The U.S. market growth is supported by the presence of major biotechnology and pharmaceutical companies, high research activity in genomics and precision medicine, and the early adoption of advanced diagnostic tools in clinical practice.

• When analyzed by product, the instrument segment accounted for the largest revenue share at 40.0% in 2024. This dominance is driven by the increasing demand for advanced HRM analysis instruments that provide higher accuracy, efficiency, and automation in genetic testing. Continuous technological upgrades and the integration of HRM instruments into laboratories and research facilities have further supported this segment’s growth.

• By application, the detection of acquired mutations, mutation scanning, and SNP typing segment recorded the highest revenue share of 41.6% in 2024. The widespread use of HRM analysis in identifying genetic mutations and variations, which are crucial for understanding disease mechanisms and guiding targeted therapies, has made this segment the leading contributor. The increasing prevalence of genetic disorders and the rising focus on personalized medicine further drive the demand for mutation scanning and SNP typing applications.

• Based on end use, the academic research segment dominated the global HRM analysis industry, capturing the highest revenue share of 69.8% in 2024. The strong presence of universities, research institutes, and academic laboratories actively engaged in genetic and molecular biology studies has fueled this dominance. Academic institutions are also at the forefront of developing new HRM-based applications, supported by research grants and government funding, which further strengthen this segment’s leadership in the market.

Order a free sample PDF of the High Resolution Melting Analysis Market Intelligence Study, published by Grand View Research.

Market Size Forecast:

• 2024 Market Size: USD 320.7 Million

• 2030 Projected Market Size: USD 375.8 Million

• CAGR (2025-2030): 2.7%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies Market Share Insights:

Key players in the high-resolution melting (HRM) analysis industry include F. Hoffmann-La Roche Ltd., Bio Farma, QIAGEN, and several others. These companies employ a variety of strategic initiatives to strengthen their market presence and maintain competitiveness. Core strategies include focusing on superior product quality and customer service to build brand differentiation, continuously expanding product portfolios to cater to a diverse customer base, and investing heavily in research and development to enhance HRM technology and broaden its applications across multiple medical and diagnostic fields. Additionally, leading players are actively pursuing partnerships, collaborations, and joint ventures to combine expertise, share resources, and accelerate innovation, ultimately driving growth in the HRM analysis market.

Thermo Fisher Scientific is a major player in the life sciences industry, offering a wide range of products tailored to molecular diagnostics and research. The company manufactures advanced real-time PCR systems, specialized software designed for high-resolution melting analysis, and a variety of laboratory instruments, including mass spectrometers and next-generation sequencing platforms. Alongside equipment, Thermo Fisher provides essential consumables such as bioreagents and research chemicals, supporting a broad array of molecular biology applications. Its HRM-enabled products are widely used for detecting genetic variations, with significant applications in cancer diagnostics, infectious disease research, and personalized medicine, making the company a critical contributor to advancements in genetic testing and molecular diagnostics.

Bio-Rad Laboratories operates within both the life sciences and diagnostics segments, offering a comprehensive product portfolio that indirectly supports HRM analysis. Its product range includes PCR systems, gel electrophoresis equipment, immunoassay systems, and related consumables. Bio-Rad’s instruments and reagents facilitate genetic research by enabling accurate amplification, separation, and analysis of nucleic acids and proteins. In addition, the company plays a vital role in advancing molecular biology and genomics research by providing solutions that are extensively used in genetic testing, diagnostic applications, and academic research. By catering to both research and clinical laboratories, Bio-Rad contributes significantly to the broader adoption and integration of HRM analysis technologies.

Key Players

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffman-La Roche Ltd.

• Bio Farma

• QIAGEN

• Illumina, Inc.

• Agilent Technologies, Inc.

• BIOMÉRIEUX

• Meridian Bioscience, Inc.

• Novacyt

• PREMIER Biosoft

• Azura Genomics Inc.

• Canon Medical Systems Corporation

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The HRM analysis market is set for gradual yet steady growth, driven by increasing interest in precise genotyping, mutation scanning, and epigenetics. As healthcare moves toward personalized and preventive medicine, there's growing demand for accurate molecular diagnostics. Academic research remains the primary end-user segment, while clinical diagnostics is emerging as a faster-growing area. Regions with strong RD infrastructure and supportive regulatory frameworks continue to lead, though rising unmet needs in other parts of the world are pushing for wider adoption of HRM technologies.